MinorGabapentinoids (antiepileptics)×Angiotensin II receptor blockers (sartans)
Updated · Methodology
Mechanism
Gabapentin is not metabolised in the body and is excreted unchanged by the kidneys. Its renal clearance is directly proportional to creatinine clearance. It does not induce liver enzymes and does not bind to plasma proteins (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, losartan is converted to its active metabolite mainly by CYP2C9, and CYP3A4 is also involved in its metabolism (losartan SmPC, AEMPS; Cozaar label, US Food and Drug Administration, FDA). In laboratory studies, gabapentin did not inhibit the main cytochrome P450 enzymes. Only at the highest concentration did it slightly inhibit CYP2A6 (Neurontin label, FDA). Drugs that can cause hypotension as an adverse effect may increase the risk of hypotension with losartan (losartan SmPC, AEMPS). The gabapentin documents, however, mention hypotension only as a sign of anaphylaxis, and neither drug's documents name the other drug or its class (losartan and gabapentin SmPCs, AEMPS; Cozaar and Neurontin labels, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Gabapentin very commonly causes somnolence, dizziness and ataxia, which can increase the risk of falls (gabapentin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Losartan can cause symptomatic hypotension, especially after the first dose or a dose increase in people with volume or sodium depletion. Dizziness or somnolence may occur at the start of treatment (losartan SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of losartan and gabapentin need no change. No document names the pair, and their elimination pathways do not overlap (losartan and gabapentin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The gabapentin dose is based on creatinine clearance and is reduced according to the SmPC table when creatinine clearance is below 79 mL/min (gabapentin SmPC, AEMPS). During losartan treatment, renal function is checked regularly, especially with fever or dehydration (losartan SmPC, AEMPS). Volume or sodium depletion after diuretics, diarrhoea or vomiting is corrected before losartan starts, or losartan is started at a lower dose (losartan SmPC, AEMPS). People are advised not to drive or operate complex machinery until they know whether gabapentin affects these skills, because it causes somnolence and dizziness (Neurontin label, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Neurontin 300 mg cápsulas duras (gabapentina) (2026)– AEMPS, CIMA, nº registro 60621, revisión 01/2026, secciones 4.4 y 4.5
- FDA: Neurontin (gabapentin) – Prescribing Information (2026)– FDA, DailyMed SPL, Viatris Specialty, sections 5.8, 7.1 and 12.3
- AEMPS: Ficha técnica: Losartan (nº registro 67729), sección 4.5 (2025)– AEMPS, CIMA, nº registro 67729, revisión 03/2025, sección 4.5
- FDA: Cozaar (losartan potassium) prescribing information (2026)– FDA, DailyMed setid 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (Organon LLC), revised 01/2026, section 7
- AEMPS: Ficha técnica: Losartan (nº registro 67729), sección 4.4 (2025)– AEMPS, CIMA, nº registro 67729, revisión 03/2025, sección 4.4